Cost-effectiveness of Tenofovir Gel in Urban South Africa: Model Projections of HIV Impact and Threshold Product Prices

Published in BMJ Infectious Diseases, this article reports on a modeling study that used the results of the CAPRISA 004 trial of tenofovir gel to estimate the population-level impact of the gel on HIV and HSV-2 transmission and the price thresholds at which widespread product introduction would be as cost-effective as male circumcision for HIV prevention in urban South Africa.

 

Length: 
11 pages
Year: 
2014
Organization: 
London School of Hygiene & Tropical Medicine, University of the Witwatersrand, Boston University, Wits Reproductive Health and HIV Research Institute, International Partnership for Microbicides
Languages: 
English
Author(s): 
Terris-Prestholt F, Foss AM, Cox AP, Heise L, Meyer-Rath G, Delany-Moretlwe S, Mertenskoetter T, Rees H, Vickerman P, Watts CH